Skip to main content
ResearchTreatments

Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification

*November 2022*

The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of the phase 2 INSIGHT trial (NCT01982955).1

In updated findings presented at the International Association for the Study of Lung Cancer 2022 North America Conference on Lung Cancer, patients with MET amplification demonstrated a median PFS of 16.6 months (90% CI, 8.3-22.1) with tepotinib and gefitinib treatment compared with 4.2 months (90% CI, 1.4-7.0) with chemotherapy (unstratified HR, 0.13; 90% CI, 0.04-0.43). The median OS was 37.3 months (90% CI, 21.1-52.1) compared with 13.1 months (90% CI, 3.3-22.6) with tepotinib plus gefitinib vs chemotherapy, respectively (unstratified HR, 0.10; 90% CI, 0.02-0.36). Read more.